Pharmacoeconomic evaluation of finerenone combined with standard treatment regimen in the treatment of diabetic nephropathy

LIANG Hai; XIA Runan; DI Panpan; ZHAO Mengmeng; ZHANG Pengcheng; HOU Yashen; ZHANG Hong; WU Wei; YANG Miao

doi:10.6039/j.issn.1001-0408.2025.01.14

您当前的位置：

首页 >

文章列表页 >

Pharmacoeconomic evaluation of finerenone combined with standard treatment regimen in the treatment of diabetic nephropathy

更新时间：2025-09-25

- Pharmacoeconomic evaluation of finerenone combined with standard treatment regimen in the treatment of diabetic nephropathy
- ZHONGGUO YAOFANG Vol. 36, Issue 1, Pages: 86-90(2025)
- 作者机构：
  
  亳州市人民医院药学部，安徽亳州　236800
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.01.14
  CLC： R956
- Received：17 May 2024，
  
  Revised：2024-12-16，
  
  Accepted：24 December 2024，
  
  Published：15 January 2025
- 稿件说明：
移动端阅览
梁海,夏茹楠,狄潘潘,等.非奈利酮联合标准方案治疗糖尿病肾病的药物经济学评价[J].中国药房,2025,36(01):86-90.

LIANG Hai,XIA Runan,DI Panpan,et al.Pharmacoeconomic evaluation of finerenone combined with standard treatment regimen in the treatment of diabetic nephropathy[J].ZHONGGUO YAOFANG,2025,36(01):86-90.
梁海,夏茹楠,狄潘潘,等.非奈利酮联合标准方案治疗糖尿病肾病的药物经济学评价[J].中国药房,2025,36(01):86-90. DOI： 10.6039/j.issn.1001-0408.2025.01.14.

LIANG Hai,XIA Runan,DI Panpan,et al.Pharmacoeconomic evaluation of finerenone combined with standard treatment regimen in the treatment of diabetic nephropathy[J].ZHONGGUO YAOFANG,2025,36(01):86-90. DOI： 10.6039/j.issn.1001-0408.2025.01.14.

摘要

目的

对非奈利酮联合标准方案治疗糖尿病肾病（DN）的经济性进行评价。

方法

基于我国医疗服务提供者角度，在一项非奈利酮治疗DN的Ⅲ期临床试验基础上，建立非奈利酮联合标准治疗方案和标准治疗方案治疗DN的Markov模型，模拟周期为4个月，模拟时限为15年，年贴现率为5%，模拟非奈利酮联合标准治疗方案和标准治疗方案治疗DN患者终身的效果与成本；同时进行单因素敏感性分析、概率敏感性分析，以检验结果的稳健性。

结果

标准治疗方案的累计成本为579 329.54元，累计效用为8.052 4质量调整生命年（QALYs）；非奈利酮联合标准治疗方案的累计成本为332 520.61元，累计效用为8.187 4 QALYs。非奈利酮联合标准治疗方案的成本更低且效果更好。单因素敏感性分析结果显示，透析、DN3及DN4状态的效用值对增量成本-效果比的影响较大，但未影响模型的稳健性。概率敏感性分析结果显示，非奈利酮联合标准治疗方案更具经济性的概率为100%。

结论

对于DN患者，使用非奈利酮联合标准治疗方案更具有经济性，为绝对优势方案。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of finerenone combined with standard treatment regimen in the treatment of diabetic nephropathy （DN）.

METHODS

From the perspective of healthcare service providers， a Markov model was established to simulate the dynamic changes of each stage in DN patients who received finerenone combined with the standard treatment regimen or the standard treatment regimen alone based on the phase Ⅲ clinical trial study of finerenone for DN. Markov model was used to perform the cost-effectiveness of long-term effects and the costs of the two therapies with a simulation cycle of 4 months， a simulation period of 15 years and an annual discount rate of 5%. At the same time， one-way sensitivity analysis and probability sensitivity analysis were performed， and the stability of the results was validated.

RESULTS

Accumulative cost of the standard treatment regimen was 579 329.54 yuan， and the accumulative utility was 8.052 4 quality-adjusted life year （QALYs）； the accumulative cost of finerenone combined with the standard treatment regimen was 332 520.61 yuan， and the accumulative utility was 8.187 4 QALYs. Finerenone combined with the standard treatment regimen was more cost-effective. The results of one-way sensitivity analysis showed that dialysis status utility value， DN stage 3 utility value and DN stage 4 utility value had a great influence on the incremental cost-effectiveness ratio， but did not affect the robustness of the model. The results of probability sensitivity analysis showed that finerenone combined with the standard treatment regimen was more cost-effective with 100% probability.

CONCLUSIONS

For DN patients， finerenone combined with the standard treatment regimen is more cost-effective as an absolute advantage option.

关键词

Keywords

references

中华医学会糖尿病学分会，国家基本公共卫生服务项目基层糖尿病防治管理办公室 . 国家基层糖尿病肾脏病防治技术指南：2023 [J ] . 中华内科杂志， 2023 ， 62 （ 12 ）： 1394 - 1405 .

Diabetes Society of Chinese Medical Association ， Grassroots Diabetes Prevention and Management Office of National Basic Public Health Service Project . National technical guidelines for the prevention and treatment of diabetic kidney disease in primary care：2023 [J ] . Chin J Intern Med ， 2023 ， 62 （ 12 ）： 1394 - 1405 .

PAN X W ， LIN X L ， HUANG X ， et al . The burden of diabetes-related chronic kidney disease in China from 1990 to 2019 [J ] . Front Endocrinol ， 2022 ， 13 ： 892860 .

ZHANG X X ， KONG J ， YUN K . Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China：a meta-analysis of observational studies [J ] . J Diabetes Res ， 2020 ， 2020 ： 2315607 .

ALICIC R Z ， ROONEY M T ， TUTTLE K R . Diabetic kidney disease：challenges，progress，and possibilities [J ] . Clin J Am Soc Nephrol ， 2017 ， 12 （ 12 ）： 2032 - 2045 .

中华医学会肾脏病学分会专家组 . 糖尿病肾脏疾病临床诊疗中国指南 [J ] . 中华肾脏病杂志， 2021 ， 37 （ 3 ）： 255 - 304 .

Expert Group of Nephrology Society of Chinese Medical Association . Chinese guidelines for diagnosis and treatment of diabetic kidney disease [J ] . Chin J Nephrol ， 2021 ， 37 （ 3 ）： 255 - 304 .

中华医学会糖尿病学分会微血管并发症学组 . 中国糖尿病肾脏病防治指南：2021 年[J ] . 中华糖尿病杂志， 2021 ， 13 （ 8 ）： 762 - 784 .

Microvascular Complications Group of Diabetes Branch of Chinese Medical Association . Clinical guideline for the prevention and treatment of diabetic kidney disease in China：2021 edition [J ] . Chin J Diabetes Mellit ， 2021 ， 13 （ 8 ）： 762 - 784 .

BAKRIS G L ， AGARWAL R ， ANKER S D ， et al . Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes [J ] . N Engl J Med ， 2020 ， 383 （ 23 ）： 2219 - 2229 .

PITT B ， FILIPPATOS G ， AGARWAL R ， et al . Cardiovascular events with finerenone in kidney disease and type 2 diabetes [J ] . N Engl J Med ， 2021 ， 385 （ 24 ）： 2252 - 2263 .

ELSAYED N A ， ALEPPO G ， ARODA V R ， et al . 11. chronic kidney disease and risk management：standards of care in diabetes： 2023 [J ] . Diabetes Care ， 2023 ， 46 （ Suppl. 1 ）： S191 - S202.

《非奈利酮在糖尿病合并慢性肾脏病患者中应用的中国专家共识（2023版）》专家组 . 非奈利酮在糖尿病合并慢性肾脏病患者中应用的中国专家共识： 2023版 [J ] . 中华肾脏病杂志， 2023 ， 39 （ 10 ）： 800 - 808 .

Committee of Chinese Expert Consensus on the Use of Finerenone in Patients with Diabetes Mellitus and Chronic Kidney Disease . Chinese expert consensus on the use of finerenone in patients with diabetes mellitus and chronic kidney disease： 2023 edition [J ] . Chin J Nephrol ， 2023 ， 39 （ 10 ）： 800 - 808 .

《中华内科杂志》编辑委员会，盐皮质激素受体拮抗剂临床应用共识专家组 . 盐皮质激素受体拮抗剂临床应用多学科中国专家共识：2022 [J ] . 中华内科杂志， 2022 ， 61 （ 9 ）： 981 - 999 .

Editorial Committee of Chinese Journal of Internal Medicine ， Expert Group of Multidisciplinary Expert Consensus for Clinical Application of Mineralocorticoid Receptor Antagonists in China . Multidisciplinary expert consensus for clinical application of mineralocorticoid receptor antagonists in China [J ] . Chin J Intern Med ， 2022 ， 61 （ 9 ）： 981 - 999 .

林莹，唐丽丹 . 新型盐皮质激素受体拮抗剂：非奈利酮 [J ] . 中国新药与临床杂志， 2022 ， 41 （ 12 ）： 729 - 732 .

LIN Y ， TANG L D . A novel mineralocorticoid receptor antagonists：finerenone [J ] . Chin J New Drugs Clin Remedies ， 2022 ， 41 （ 12 ）： 729 - 732 .

MING J ， HONG G Q ， XU Y R ， et al . Cost-effectiveness of finerenone in addition to standard of care for patients with chronic kidney disease and type 2 diabetes in China [J ] . Adv Ther ， 2024 ， 41 （ 8 ）： 3138 - 3158 .

唐璇璇，董邓波，邹圣强，等 . 1990－2019年中国糖尿病肾病疾病负担分析及发病预测研究 [J ] . 现代预防医学， 2024 ， 51 （ 13 ）： 2336 - 2341，2392 .

TANG X X ， DONG D B ， ZOU S Q ， et al . Disease burden analysis and incidence prediction of diabetic nephropathy in China from 1990 to 2019 [J ] . Mod Prev Med ， 2024 ， 51 （ 13 ）： 2336 - 2341，2392 .

ZHENG C L ， WU J N ， LI N ， et al . Cost-effectiveness of finerenone added to standard of care for patients with type 2 diabetes-related chronic kidney disease in the United States [J ] . Diabetes Obes Metab ， 2025 ， 27 （ 1 ）： 165 - 173 .

QUIST S W ， VAN SCHOONHOVEN A V ， BAKKER S J L ， et al . Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in the Netherlands [J ] . Cardiovasc Diabetol ， 2023 ， 22 （ 1 ）： 328 .

HUMLE K ， KLANGER B ， KOLKHOF P ， et al . Summary of research：cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease：the FIDELITY pooled analysis [J ] . Diabetes Ther ， 2024 ， 15 （ 9 ）： 1861 - 1864 .

AGARWAL R ， FILIPPATOS G ， PITT B ， et al . Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease：the FIDELITY pooled analysis [J ] . Eur Heart J ， 2022 ， 43 （ 6 ）： 474 - 484 .

Views

192

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmacoeconomic evaluation of trastuzumab deruxtecan versus chemotherapy in the second-line treatment of advanced breast cancer with HER-2 low expression

Pharmacoeconomic evaluation of omalizumab in the treatment of severe allergic asthma

Pharmacoeconomics of ivabradine in the treatment of CHF in the context of “Quadruple Therapy”

Study on pharmacoeconomic evaluation of vericiguat in the treatment of heart failure with reduced ejection fraction

Cost-effectiveness of regorafenib for hepatocellular carcinoma after failure of sorafenib

Related Author

LI Xue

JIA Caifeng

ZHENG Ying

ZHANG Sen

WANG Meiqi

WANG Mingxia

XIONG Chaogang

ZHU Yurong

Related Institution

Breast Center， the Fourth Hospital of Hebei Medical University

Dept. of Clinical Pharmacology， the Fourth Hospital of Hebei Medical University

Dept. of Pharmacy， the Fourth Hospital of Hebei Medical University

Dept. of Clinical Pharmacy， Shaanxi Second Provincial People’s Hospital

Dept. of Pharmacy， the First Affiliated Hospital of Xi’an Jiaotong University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰